The combination of CRP isoforms with oxLDL decreases TNF‑α and IL‑6 release by U937‑derived macrophages

Krayem,Imtissal; Bazzi,Samer; Karam,Marc

doi:10.3892/br.2017.949

The combination of CRP isoforms with oxLDL decreases TNF‑α and IL‑6 release by U937‑derived macrophages

Authors:
- Imtissal Krayem
- Samer Bazzi
- Marc Karam
View Affiliations

Affiliations: Department of Biology, Faculty of Sciences, University of Balamand, Deir El Balamand, El‑Koura, 100‑Tripoli, Lebanon
Published online on: July 21, 2017 https://doi.org/10.3892/br.2017.949
Pages: 272-276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

C‑reactive protein (CRP) and oxidized low density lipoprotein (oxLDL) serve major roles at both early and advanced stages of atherosclerosis. CRP exists in two isoforms, monomeric (m) and pentameric (p), that bring about pro‑ or anti‑inflammatory effects in macrophages. In addition, CRP may form a complex with oxidized low‑density lipoprotein (oxLDL) via phosphatidylcholine, thus decreasing its pro‑inflammatory effects within macrophages. The aim of the present study was to investigate the single and the combined effects of mCRP, pCRP and oxLDL on U937‑derived macrophages. In the current study, U937‑derived macrophages were treated in vitro with different combinations of CRP isoforms with or without oxLDL. The levels of major inflammatory cytokines [interleukin (IL)‑1β, IL‑6, IL‑8 and tumor necrosis factor (TNF)‑α] along with the production of reactive oxygen species (ROS) were determined. TNF‑α and IL‑6 levels were significantly decreased (P<0.05) by the effect of mCRP and pCRP combined with oxLDL. No significant changes were observed in IL‑1β, IL‑8 or ROS levels.

View Figures

View References

1	Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R and Moran AE: Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 46:328–338. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hattori Y, Matsumura M and Kasai K: Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res. 58:186–195. 2003. View Article : Google Scholar : PubMed/NCBI
3	Eisenhardt SU, Thiele JR, Bannasch H, Stark GB and Peter K: C-reactive protein: How conformational changes influence inflammatory properties. Cell Cycle. 8:3885–3892. 2009. View Article : Google Scholar : PubMed/NCBI
4	Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, et al: Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 105:128–137. 2009. View Article : Google Scholar : PubMed/NCBI
5	Khreiss T, József L, Potempa LA and Filep JG: Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 109:2016–2022. 2004. View Article : Google Scholar : PubMed/NCBI
6	Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, Potempa LA and Galle J: Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation. 112:1016–1023. 2005. View Article : Google Scholar : PubMed/NCBI
7	Eisenhardt SU, Habersberger J and Peter K: Monomeric C-reactive protein generation on activated platelets: The missing link between inflammation and atherothrombotic risk. Trends Cardiovasc Med. 19:232–237. 2009. View Article : Google Scholar : PubMed/NCBI
8	Filep JG: Platelets affect the structure and function of C-reactive protein. Circ Res. 105:109–111. 2009. View Article : Google Scholar : PubMed/NCBI
9	Khreiss T, József L, Potempa LA and Filep JG: Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res. 97:690–697. 2005. View Article : Google Scholar : PubMed/NCBI
10	Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002. View Article : Google Scholar : PubMed/NCBI
11	Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, et al: The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res. 48:768–781. 2007. View Article : Google Scholar : PubMed/NCBI
12	Chang MK, Hartvigsen K, Ryu J, Kim Y and Han KH: The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine. J Inflamm (Lond). 9:422012. View Article : Google Scholar : PubMed/NCBI
13	Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U and Hansson GK: Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 145:33–43. 1999. View Article : Google Scholar : PubMed/NCBI
14	Qiu G, Ho AC, Yu W and Hill JS: Suppression of endothelial or lipoprotein lipase in THP-1 macrophages attenuates proinflammatory cytokine secretion. J Lipid Res. 48:385–394. 2007. View Article : Google Scholar : PubMed/NCBI
15	Jovinge S, Ares MP, Kallin B and Nilsson J: Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol. 16:1573–1579. 1996. View Article : Google Scholar : PubMed/NCBI
16	Eruslanov E and Kusmartsev S: Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol. 594:57–72. 2010. View Article : Google Scholar : PubMed/NCBI
17	Uzui H, Harpf A, Liu M, Doherty TM, Shukla A, Chai NN, Tripathi PV, Jovinge S, Wilkin DJ, Asotra K, et al: Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: Role of activated macrophages and inflammatory cytokines. Circulation. 106:3024–3030. 2002. View Article : Google Scholar : PubMed/NCBI
18	Kaneto H, Katakami N, Matsuhisa M and Matsuoka TA: Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm. 2010:4538922010. View Article : Google Scholar : PubMed/NCBI
19	Chávez-Sánchez L, Chávez-Rueda K, Legorreta-Haquet MV, Zenteno E, Ledesma-Soto Y, Montoya-Díaz E, Tesoro-Cruz E, Madrid-Miller A and Blanco-Favela F: The activation of CD14, TLR4, and TLR2 by mmLDL induces IL-1beta, IL-6, and IL-10 secretion in human monocytes and macrophages. Lipids Health Dis. 9:1172010. View Article : Google Scholar : PubMed/NCBI
20	Galve-de Rochemonteix B, Wiktorowicz K, Kushner I and Dayer JM: C-reactive protein increases production of IL-1 alpha, IL-1 beta, and TNF-alpha and expression of mRNA by human alveolar macrophages. J Leukoc Biol. 53:439–445. 1993.PubMed/NCBI
21	Pue CA, Mortensen RF, Marsh CB, Pope HA and Wewers MD: Acute phase levels of C-reactive protein enhance IL-1 beta and IL-1ra production by human blood monocytes but inhibit IL-1 beta and IL-1ra production by alveolar macrophages. J Immunol. 156:1594–1600. 1996.PubMed/NCBI
22	Gershov D, Kim S, Brot N and Elkon KB: C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med. 192:1353–1364. 2000. View Article : Google Scholar : PubMed/NCBI
23	Taylor KE and van den Berg CW: Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology. 120:404–411. 2007. View Article : Google Scholar : PubMed/NCBI
24	Adan A, Kiraz Y and Baran Y: Cell proliferation and cytotoxicity assays. Curr Pharm Biotechnol. 17:1213–1221. 2016. View Article : Google Scholar : PubMed/NCBI
25	Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P and Pedersen BK: A high plasma concentration of TNF-αlpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 54:M357–M364. 1999. View Article : Google Scholar : PubMed/NCBI
26	Hansson GK and Hermansson A: The immune system in atherosclerosis. Nat Immunol. 12:204–212. 2011. View Article : Google Scholar : PubMed/NCBI
27	Devaraj S, Davis B, Simon SI and Jialal I: CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol. 291:H1170–H1176. 2006. View Article : Google Scholar : PubMed/NCBI
28	Bruunsgaard H, Skinhøj P, Pedersen AN, Schroll M and Pedersen BK: Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol. 121:255–260. 2000. View Article : Google Scholar : PubMed/NCBI
29	Huber SA, Sakkinen P, Conze D, Hardin N and Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 19:2364–2367. 1999. View Article : Google Scholar : PubMed/NCBI
30	Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J and Jovinge S: Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 24:2137–2142. 2004. View Article : Google Scholar : PubMed/NCBI
31	Hansson GK and Libby P: The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol. 6:508–519. 2006. View Article : Google Scholar : PubMed/NCBI
32	Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N and Matsushima K: Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol. 56:559–564. 1994.PubMed/NCBI
33	Zhao XQ, Zhang MW, Wang F, Zhao YX, Li JJ, Wang XP, Bu PL, Yang JM, Liu XL, Zhang MX, et al: CRP enhances soluble LOX-1 release from macrophages by activating TNF-α converting enzyme. J Lipid Res. 52:923–933. 2011. View Article : Google Scholar : PubMed/NCBI
34	Thiele JR, Zeller J, Bannasch H, Stark GB, Peter K and Eisenhardt SU: Targeting C-reactive protein in inflammatory disease by preventing conformational changes. Mediators Inflamm. 2015:3724322015. View Article : Google Scholar : PubMed/NCBI